宜明昂科-B:收到与AXION BIO的授权及合作里程碑付款

Core Viewpoint - The announcement highlights the ongoing collaboration between the company and Instil, with significant milestone payments received, indicating progress in the development of a dual-specificity antibody for cancer treatment [1] Group 1 - The company has received a milestone payment of 10 million USD from Instil since signing the licensing and collaboration agreement with AXION BIO on August 1, 2024 [1] - The total payments received under the agreement have reached 30 million USD as of the date of the announcement, reflecting a commitment to continued progress with Instil [1] - IMM2510/AXN-2510 is a dual-specificity antibody targeting PD-L1 and VEGF, currently being developed for the treatment of various solid tumors [1]